<#-- Rebranding: Header Logo--> <#-- Rebranding: Footer Logo-->

6 Generic Products That Are Just As Good

AAA

Is Generic Just As Good?

Money-strapped shoppers are choosing generic over big name brands in their supermarket aisles. Consumers generally agree that generic diapers, toilet paper, condiments and cheese simply aren't worth the savings. However, there are a few generic products that make the grade. Here are 6 generics that are just as good as the real thing.

  1. No results found.
Related Articles
  1. Insights

    How Teva Is Fighting (and Losing) the Big Pharma Battle

    Teva is still the largest generics drugmaker in the world but struggles to catch up with big pharmaceutical companies boosted by brand name drugs.
  2. Investing

    Novartis Eyes $8B Buy of Generic Drug Firm (NVS)

    The potential $8 billion acquisition can help Novartis become the third-largest generic drug company in the US.
  3. Investing

    Teva Launches Generic Version of Beyaz (TEVA)

    Teva Pharmaceutical rolled out Rajani, an oral contraceptive that's the generic version of Bayer's Beyaz birth control pill.
  4. Investing

    Teva Expands Both Branded, Generics (TEVA, AGN)

    Teva has purchased Allergan's generics business but will continue to focus on its specialized branded drugs.
  5. Investing

    Endo Settles FTC 'Pay-for-Delay' Allegations

    Endo resolved a dispute with the FTC alleging that it paid rivals to delay generic drug rollouts.
  6. Investing

    Teva Blames FDA Generics Approvals For Its Decline

    The Israeli pharmaceutical giant blames a $6.1B writedown in Q2 on increased competition in the U.S.
  7. Investing

    Big Week Ahead for Big Pharma: Roche, GSK, Sanofi, Mylan

    Big pharma companies eagerly await key decisions on drugs from the FDA next week.
  8. Investing

    ANI Pharmaceuticals 3Q Net Beats Street (ANIP)

    ANI Pharmaceuticals 3Q earnings and revenues beat analyst projections.
  9. Investing

    AstraZeneca Cuts 700 Jobs, Citing Falling Revenues

    Falling revenues from its best-selling drugs have led to severe cost-cutting measures.
  10. Investing

    Pfizer Exits Brazil: Teva Is Suitor (PFE, TEVA)

    Pfizer is planning to exit the Brazilian market as it puts its generic drug joint venture stake up for sale. Teva and Mylan are possible bidders for the asset.
Trading Center